Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA : Effect Pigments for Architecture: Merck Exhibits at the Middle East Coatings Show 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2012 | 10:24am CEST

Darmstadt/Germany, March 5, 2012 - Merck will be presenting its effect pigments for architecture at the Middle East Coatings Show in Dubai from March 12 to 14, 2012. This exhibition is the most important platform for the coatings sector in the Middle East and the Gulf region. The focus of the exhibition will be on architectural applications, which have been seeing rapid growth in the region for the past several years. The trend toward gold and silver shades, which can currently be seen in lifestyle products and interior designs, is also being reflected in architecture.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
05/23 PFIZER : Merck`s Keytruda nabs I-O`s third bladder cancer approval this month
05/23 ABLYNX : Novel nanobody to start clinical development in osteoarthritis - Ablynx..
05/22 MERCK : ‘It’s not you. It’s your thyroid.’ Campaign Laun..
05/22 MERCK : Acquisition of Merck and Millipore brands.
05/19 MERCK : 100 Healthy Years – Are Kids Prepared?
05/18 MERCK : EpiThany Announces Clinical Collaboration with Merck KGaA, Darmstadt, Ge..
05/18 LIQUID CRYSTALS FOR NEW OPTICAL APPL : Merck Collaborates with the University of..
05/18 MERCK : Continues to Grow Profitably in the First Quarter
05/18DJMERCK : Beats Expectations, Guidance Cautious -- Market Talk
05/18DJMERCK : 1Q Net Profit Falls 12%
More news
Sector news : Specialty & Advanced Pharmaceuticals
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
05/18 Merck's (MKGAF) on Q1 2017 Results - Earnings Call Transcript
05/18 Merck KGaA reports Q1 results
05/15 Turmoil In Immuno-Oncology
05/10 Tecentriq Failure Puts Accelerated Approval In A Spin
05/10 Physicians Look For Progress In Mesothelioma
Advertisement
Financials (€)
Sales 2017 15 596 M
EBIT 2017 3 318 M
Net income 2017 1 865 M
Debt 2017 9 690 M
Yield 2017 1,22%
P/E ratio 2017 24,16
P/E ratio 2018 20,69
EV / Sales 2017 1,49x
EV / Sales 2018 1,32x
Capitalization 13 577 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 112 €
Spread / Average Target 6,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA5.95%15 477
ABBVIE INC5.29%104 150
KYOWA HAKKO KIRIN CO L..25.15%10 588
JAZZ PHARMACEUTICALS P..37.67%9 123
CONVATEC GROUP PLC35.70%7 631
ZHANGZHOU PIENTZEHUANG..24.24%4 901
More Results